Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Dementia a Qualifying Condition for Medical Cannabis? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

In the United Kingdom, medical cannabis can legally be prescribed only by specialist doctors under very specific circumstances. According to NICE guidance (NG144) and NHS advice, these include rare forms of epilepsy, chemotherapy-related nausea, and muscle spasticity caused by multiple sclerosis. 

Dementia is not currently listed as a qualifying condition for medical cannabis in the UK. This means it cannot be prescribed routinely for Alzheimer’s disease or other types of dementia outside a formal clinical trial or a strictly monitored, off-label case. 

Can medical cannabis be accessed legally for women’s health?

What The Evidence Shows 

Research over the past few years has explored whether cannabinoids such as THC or CBD could ease symptoms like agitation, anxiety, or sleep disruption in people with dementia. However, studies have shown inconsistent and often minimal benefits. 

A review published in the BMJ and findings summarised by Alzheimer’s Society UK conclude that there is not enough reliable evidence to support cannabis-based products for dementia symptoms. Safety concerns, particularly confusion, sedation, and increased fall risk, remain significant in older adults. 

The UK Position on Prescribing 

Under UK law, medical cannabis is considered only when all licensed treatments have failed, and the potential benefits outweigh the risks. In the case of dementia, NICE and NHS policy state that there is insufficient evidence to justify prescribing cannabis-based medicines, either for cognitive symptoms or behavioural changes. Clinicians may apply to use these treatments on an exceptional, off-label basis, but this is rare and typically limited to clinical research settings. 

Clinical Bottom Line 

  • Dementia is not a qualifying condition for medical cannabis in the UK. 
  • NICE and NHS guidance do not support routine prescribing for dementia. 
  • Evidence for benefits is weak and inconsistent, mainly limited to small pilot studies. 
  • Side effects such as confusion, dizziness, and falls are common in older patients. 
  • Use should only occur in clinical trials or under specialist supervision. 

About AlleviMed   

If you are considering whether medical cannabis might be appropriate, services such as AlleviMed (launching soon) can help assess eligibility for conditions that meet current UK guidelines. Their consultations aim to ensure any potential use of cannabis-based medicines is safe, legal, and clinically justified. 

Takeaway 

At present, dementia does not qualify for medical cannabis treatment in the UK. NICE and NHS experts agree that evidence remains too limited to recommend its use, and further research is needed before it can be considered a safe or effective therapy. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories